Mirum Pharmaceuticals, Inc. (MIRM) NASDAQ
109.16
+2.28(+2.13%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
109.16
+2.28(+2.13%)
Currency In USD
Address
950 Tower Lane
Foster City, CA 94404
United States of America (the)
Phone
650 667 4085
Website
Sector
Healthcare
Industry
Biotechnology
Employees
334
First IPO Date
July 18, 2019
| Name | Title | Pay | Year Born |
| Christopher Peetz | Chief Executive Officer & Director | 1.83M | 1979 |
| Lara Longpre | Chief Development Officer | 678,200 | 1970 |
| Joanne J. Quan | Chief Medical Officer | 1M | 1964 |
| Eric H. Bjerkholt | Chief Financial Officer | 1M | 1960 |
| Peter Radovich | Chief Operating Officer & President | 1.16M | 1978 |
| Jean-Luc Girardet | Chief Technical Officer | 0 | N/A |
| Meredith Kiernan | Senior Director of Global Corporate Communications | 0 | N/A |
| Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations | 0 | N/A |
| Vinita Kumar | Senior Vice President of Quality | 0 | N/A |
| Erin Campany | Chief People Officer | 0 | 1968 |
| Douglas T. Sheehy | Chief Legal Officer & Secretary | 0 | 1967 |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.